Using single-cell genomics and gene therapy technologies, Decibel Therapeutics aims to restore hearing and balance function through its research and drug development platform. The company's lead drug candidate, DB-OTO, is designed to provide hearing to individuals with profound hearing loss caused by an OTOF deficiency. Decibel Therapeutics also has exclusive license agreements with the University of Florida and the University of California, San Francisco for gene therapy technology to restore hearing in individuals with congenital hearing loss. With a pipeline of innovative therapies, Decibel Therapeutics is dedicated to addressing the unmet need in the field of hearing and balance disorders.